Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
2001 1
2003 1
2004 1
2005 2
2006 1
2007 4
2008 2
2009 4
2010 5
2011 6
2012 5
2013 4
2014 15
2015 3
2016 17
2017 15
2018 27
2019 36
2020 42
2021 52
2022 46
2023 47
2024 23

Text availability

Article attribute

Article type

Publication date

Search Results

314 results

Results by year

Filters applied: . Clear all
Page 1
Identifying patients with NTRK fusion cancer.
Solomon JP, Benayed R, Hechtman JF, Ladanyi M. Solomon JP, et al. Ann Oncol. 2019 Nov 1;30(Suppl_8):viii16-viii22. doi: 10.1093/annonc/mdz384. Ann Oncol. 2019. PMID: 31738428 Free PMC article. Review.
Due to the efficacy of tropomyosin receptor kinase (TRK) inhibitor therapy and the recent Food and Drug Administration approval of larotrectinib, it is now clinically important to accurately and efficiently identify patients with neurotrophic TRK (NTRK) fusion-driven cancer …
Due to the efficacy of tropomyosin receptor kinase (TRK) inhibitor therapy and the recent Food and Drug Administration approval of larotrect …
NTRK fusion-positive cancers and TRK inhibitor therapy.
Cocco E, Scaltriti M, Drilon A. Cocco E, et al. Nat Rev Clin Oncol. 2018 Dec;15(12):731-747. doi: 10.1038/s41571-018-0113-0. Nat Rev Clin Oncol. 2018. PMID: 30333516 Free PMC article. Review.
NTRK gene fusions involving either NTRK1, NTRK2 or NTRK3 (encoding the neurotrophin receptors TRKA, TRKB and TRKC, respectively) are oncogenic drivers of various adult and paediatric tumour types. ...Despite durable disease control in many patients, advanced-stage NTRK fus …
NTRK gene fusions involving either NTRK1, NTRK2 or NTRK3 (encoding the neurotrophin receptors TRKA, TRKB and TRKC, respectively) are …
Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma.
Jones DT, Hutter B, Jäger N, Korshunov A, Kool M, Warnatz HJ, Zichner T, Lambert SR, Ryzhova M, Quang DA, Fontebasso AM, Stütz AM, Hutter S, Zuckermann M, Sturm D, Gronych J, Lasitschka B, Schmidt S, Seker-Cin H, Witt H, Sultan M, Ralser M, Northcott PA, Hovestadt V, Bender S, Pfaff E, Stark S, Faury D, Schwartzentruber J, Majewski J, Weber UD, Zapatka M, Raeder B, Schlesner M, Worth CL, Bartholomae CC, von Kalle C, Imbusch CD, Radomski S, Lawerenz C, van Sluis P, Koster J, Volckmann R, Versteeg R, Lehrach H, Monoranu C, Winkler B, Unterberg A, Herold-Mende C, Milde T, Kulozik AE, Ebinger M, Schuhmann MU, Cho YJ, Pomeroy SL, von Deimling A, Witt O, Taylor MD, Wolf S, Karajannis MA, Eberhart CG, Scheurlen W, Hasselblatt M, Ligon KL, Kieran MW, Korbel JO, Yaspo ML, Brors B, Felsberg J, Reifenberger G, Collins VP, Jabado N, Eils R, Lichter P, Pfister SM; International Cancer Genome Consortium PedBrain Tumor Project. Jones DT, et al. Nat Genet. 2013 Aug;45(8):927-32. doi: 10.1038/ng.2682. Epub 2013 Jun 30. Nat Genet. 2013. PMID: 23817572 Free PMC article.
Here we describe whole-genome sequencing of 96 pilocytic astrocytomas, with matched RNA sequencing (n = 73), conducted by the International Cancer Genome Consortium (ICGC) PedBrain Tumor Project. We identified recurrent activating mutations in FGFR1 and PTPN11 and new N …
Here we describe whole-genome sequencing of 96 pilocytic astrocytomas, with matched RNA sequencing (n = 73), conducted by the International …
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, Blakely CM, Seto T, Cho BC, Tosi D, Besse B, Chawla SP, Bazhenova L, Krauss JC, Chae YK, Barve M, Garrido-Laguna I, Liu SV, Conkling P, John T, Fakih M, Sigal D, Loong HH, Buchschacher GL Jr, Garrido P, Nieva J, Steuer C, Overbeck TR, Bowles DW, Fox E, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Demetri GD; trial investigators. Doebele RC, et al. Lancet Oncol. 2020 Feb;21(2):271-282. doi: 10.1016/S1470-2045(19)30691-6. Epub 2019 Dec 11. Lancet Oncol. 2020. PMID: 31838007 Free PMC article.
We present an integrated efficacy and safety analysis of patients with metastatic or locally advanced solid tumours harbouring oncogenic NTRK1, NTRK2, and NTRK3 gene fusions treated in three ongoing, early-phase trials. ...All patients had an Eastern Cooperative Oncology G …
We present an integrated efficacy and safety analysis of patients with metastatic or locally advanced solid tumours harbouring oncogenic NTR …
Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers.
Jiang T, Wang G, Liu Y, Feng L, Wang M, Liu J, Chen Y, Ouyang L. Jiang T, et al. Acta Pharm Sin B. 2021 Feb;11(2):355-372. doi: 10.1016/j.apsb.2020.05.004. Epub 2020 May 23. Acta Pharm Sin B. 2021. PMID: 33643817 Free PMC article. Review.
Tropomyosin receptor kinase A, B and C (TRKA, TRKB and TRKC), which are well-known members of the cell surface receptor tyrosine kinase (RTK) family, are encoded by the neurotrophic receptor tyrosine kinase 1, 2 and 3 (NTRK1, NTRK2 and NTRK3) genes, respectively. TRKs can …
Tropomyosin receptor kinase A, B and C (TRKA, TRKB and TRKC), which are well-known members of the cell surface receptor tyrosine kinase (RTK …
A review of NTRK fusions in cancer.
Manea CA, Badiu DC, Ploscaru IC, Zgura A, Bacinschi X, Smarandache CG, Serban D, Popescu CG, Grigorean VT, Botnarciuc V. Manea CA, et al. Ann Med Surg (Lond). 2022 Jun 13;79:103893. doi: 10.1016/j.amsu.2022.103893. eCollection 2022 Jul. Ann Med Surg (Lond). 2022. PMID: 35860155 Free PMC article. Review.
The members of this receptor family are TRKA, TRKB and TRKC and they are encoded by the genes NTRK1, NTRK2 and NTRK3. Alterations of NTRK genes can induce carcinogenesis both in neurogenic and non-neurogenic cells. ...The presence of NTRK 1 gene fusion is associated, in so …
The members of this receptor family are TRKA, TRKB and TRKC and they are encoded by the genes NTRK1, NTRK2 and NTRK3. Alterations of …
Circular RNA_0006014 promotes breast cancer progression through sponging miR-885-3p to regulate NTRK2 and PIK3/AKT pathway.
Zhou X, Jian W, Luo Q, Zheng W, Deng X, Wang X, Borkhuu O, Ji C, Li D, Fang L. Zhou X, et al. Aging (Albany NY). 2022 Apr 5;14(7):3105-3128. doi: 10.18632/aging.203996. Epub 2022 Apr 5. Aging (Albany NY). 2022. PMID: 35383130 Free PMC article.
Breast cancer is the most common cancer in women worldwide. Numerous reports have demonstrated that circRNAs play an essential role in regulating the biological characteristics of breast cancer. ...Our results demonstrated that hsa_circ_0006014 promotes breas …
Breast cancer is the most common cancer in women worldwide. Numerous reports have demonstrated that circRNAs play an essential …
Molecular characterization of cancers with NTRK gene fusions.
Gatalica Z, Xiu J, Swensen J, Vranic S. Gatalica Z, et al. Mod Pathol. 2019 Jan;32(1):147-153. doi: 10.1038/s41379-018-0118-3. Epub 2018 Aug 31. Mod Pathol. 2019. PMID: 30171197 Free article.
Targeted inhibitors of neurotropic tyrosine kinases are highly effective in selected patients with gene fusions involving NTRK1, NTRK2, or NTRK3. These fusions are consistently detected in rare cancer types (e.g., secretory breast carcinoma and congenital infantile …
Targeted inhibitors of neurotropic tyrosine kinases are highly effective in selected patients with gene fusions involving NTRK1, NTRK2 …
NTRK2 is an oncogene and associated with microRNA-22 regulation in human gastric cancer cell lines.
Hu J, Huang Y, Wu Y, Liu F, Sun D, Wang K, Qu H. Hu J, et al. Tumour Biol. 2016 Nov;37(11):15115-15123. doi: 10.1007/s13277-016-5337-y. Epub 2016 Sep 23. Tumour Biol. 2016. PMID: 27662840
Gene expression of NTRK2 was compared between non-carcinoma gastric epithelial cells and gastric cancer (GC) cells by quantitative RT-PCR (qRT-PCR). ...NTRK2 is an oncogene and reversely associated with miR-22 in regulating in vitro cancer development …
Gene expression of NTRK2 was compared between non-carcinoma gastric epithelial cells and gastric cancer (GC) cells by quantita …
Identifying patients with NTRK fusion cancer.
Solomon JP, Benayed R, Hechtman JF, Ladanyi M. Solomon JP, et al. Ann Oncol. 2019 Nov;30 Suppl 8:viii16-viii22. doi: 10.1093/annonc/mdz384. Epub 2019 Dec 24. Ann Oncol. 2019. PMID: 32223934 Review.
Due to the efficacy of tropomyosin receptor kinase (TRK) inhibitor therapy and the recent Food and Drug Administration approval of larotrectinib, it is now clinically important to accurately and efficiently identify patients with neurotrophic TRK (NTRK) fusion-driven cancer …
Due to the efficacy of tropomyosin receptor kinase (TRK) inhibitor therapy and the recent Food and Drug Administration approval of larotrect …
314 results